Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee

ClinicalTrials.gov ID: NCT03291470

Public ClinicalTrials.gov record NCT03291470. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 4:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 3 Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee

Study identification

NCT ID
NCT03291470
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Kolon TissueGene, Inc.
Industry
Enrollment
531 participants

Conditions and interventions

Interventions

  • Placebo Control Biological
  • TG-C Biological

Biological

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 8, 2021
Primary completion
Mar 5, 2024
Completion
Apr 30, 2026
Last update posted
May 5, 2026

2021 – 2026

United States locations

U.S. sites
27
U.S. states
14
U.S. cities
26
Facility City State ZIP Site status
Nebojsa Skrepnik Tucson Arizona 85712
Steve Sitar Anaheim California 92801
Stuart Silverman Beverly Hills California 90211
Samy Metyas Covina California 91722
Bassil Aish Huntington Beach California 92647
Peter Hanson La Mesa California 91942
Duane Anderson San Diego California 92120
Miguel Trevino Clearwater Florida 33756
Jan Hommen Doral Florida 33126
Mira Baron West Palm Beach Florida 33409
Richard Radnovich Boise Idaho 83713
Thomas Schnitzer Chicago Illinois 60611
Nathan Rimmke Rochester Hills Michigan 48307
Larkin Wadsworth St Louis Missouri 63141
Robby Ann Quintos Las Vegas Nevada 89109
Igor Grosman Brooklyn New York 11235
Jonathan Samuels New York New York 10016
Minal Desai Durham North Carolina 27704
Jeremy Hoff Wilmington North Carolina 28412
Priyesh Mehta Dayton Ohio 45432
Edward Tavel Charleston South Carolina 29406
Durga Tanneru Dallas Texas 75230
Manjoo Sharma Lewisville Texas 75057
Haresh Boghara Red Oak Texas 75154
Leonel Reyes San Antonio Texas 78215
Lisa Blair San Antonio Texas 78229
David Scott Spokane Washington 99218

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03291470, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 5, 2026 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03291470 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →